Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Aug;10(8):e9431.
doi: 10.15252/emmm.201809431.

AAV-mediated gene therapy as a strategy to fight obesity and metabolic diseases

Carlos Henrique Sponton  1   2   3 , Shingo Kajimura  1   2   3
Affiliations
Comment

AAV-mediated gene therapy as a strategy to fight obesity and metabolic diseases

Carlos Henrique Sponton et al. EMBO Mol Med. 2018 Aug.

Abstract

The fibroblast growth factor 21 (FGF21) is a member of the FGF superfamily that now comprises 22 members identified in humans. Unlike the canonical role of most FGF family members, FGF21 is released into the circulation and acts as an endocrine hormone by binding with low affinity to FGF receptors (FGFRs) as well as to the co‐receptor β‐klotho in the target cells to trigger the ERK1/2 and MAPKs signaling pathways. Described initially as a hepatokine, subsequent studies identified significant amounts of FGF21 transcript in the pancreas, the adipose tissue, and the skeletal muscle. FGF21 expression is highly regulated by environmental stimuli such as starvation, ketogenic diet, cold exposure, and exercise.

PubMed Disclaimer

Figures

Figure 1
Figure 1. AAV‐FGF21 gene therapy improves metabolic health in diet‐induced obesity mice (DIO)
Jimenez and colleagues demonstrated that adeno‐associated virus (AAV)‐mediated FGF21 expression promotes the following metabolic benefits in indicated tissues.
See this image and copyright information in PMC

Comment on

  • FGF21 gene therapy as treatment for obesity and insulin resistance.
    Jimenez V, Jambrina C, Casana E, Sacristan V, Muñoz S, Darriba S, Rodó J, Mallol C, Garcia M, León X, Marcó S, Ribera A, Elias I, Casellas A, Grass I, Elias G, Ferré T, Motas S, Franckhauser S, Mulero F, Navarro M, Haurigot V, Ruberte J, Bosch F. Jimenez V, et al. EMBO Mol Med. 2018 Aug;10(8):e8791. doi: 10.15252/emmm.201708791. EMBO Mol Med. 2018. PMID: 29987000 Free PMC article.

References

    1. Bon Durant LD, Ameka M, Naber MC, Markan KR, Idiga SO, Acevedo MR, Walsh SA, Ornitz DM, Potthoff MJ (2017) FGF21 regulates metabolism through adipose‐dependent and ‐independent mechanisms. Cell Metab 25: 935–944.e4 - PMC - PubMed
    1. Degirolamo C, Sabbà C, Moschetta A (2016) Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov 15: 51–69 - PubMed
    1. Emanuelli B, Vienberg SG, Smyth G, Cheng C, Stanford KI, Arumugam M, Michael MD, Adams AC, Kharitonenkov A, Kahn CR (2014) Interplay between FGF21 and insulin action in the liver regulates metabolism. J Clin Invest 124: 515–527 - PMC - PubMed
    1. Ikeda K, Kang Q, Yoneshiro T, Camporez JP, Maki H, Homma M, Shinoda K, Chen Y, Lu X, Maretich P et al (2017) UCP1‐independent signaling involving SERCA2b‐mediated calcium cycling regulates beige fat thermogenesis and systemic glucose homeostasis. Nat Med 23: 1454–1465 - PMC - PubMed
    1. Jimenez V, Jambrina C, Casana E, Sacristan V, Muñoz S, Darriba S, Rodó J, Mallo C, Garcia M, León X et al (2018) FGF21 gene therapy as treatment for obesity and insulin resistance. EMBO Mol Med 10: e8791 - PMC - PubMed

Publication types

Substances